United States:
Episode 50: Pharma Pricing Climate In Washington
24 February 2020
Buchanan Ingersoll & Rooney PC
To print this article, all you need is to be registered or login on Mondaq.com.
Mike Strazzella, head of federal government relations for
Buchanan Ingersoll & Rooney, talks about pricing issues in the
pharmaceutical industry, the challenges he encounters, and what he
believes needs to change in the industry going forward.
You can listen and/or download the episode on SoundCloud,
or directly through iTunes, GooglePlay, Stitcher, and Overcast.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...